Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2022

Open Access 01-12-2022 | Dengue Virus | Research

Identification of stage-related and severity-related biomarkers and exploration of immune landscape for Dengue by comprehensive analyses

Authors: Nan Xiong, Qiangming Sun

Published in: Virology Journal | Issue 1/2022

Login to get access

Abstract

Background

At present, there are still no specific therapeutic drugs and appropriate vaccines for Dengue. Therefore, it is important to explore distinct clinical diagnostic indicators.

Methods

In this study, we combined differentially expressed genes (DEGs) analysis, weighted co-expression network analysis (WGCNA) and Receiver Operator Characteristic Curve (ROC) to screen a stable and robust biomarker with diagnosis value for Dengue patients. CIBERSORT was used to evaluate immune landscape of Dengue patients. Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and Gene set enrichment analysis (GSEA) were applied to explore potential functions of hub genes.

Results

CD38 and Plasma cells have excellent Area Under the Curve (AUC) in distinguishing clinical stages for Dengue patients, and activated memory CD4+ T cells and Monocytes have good AUC for this function. ZNF595 has acceptable AUC in discriminating dengue hemorrhagic fever (DHF) from dengue fever (DF) in whole acute stages. Analyzing any serotype, we can obtain consistent results. Negative inhibition of viral replication based on GO, KEGG and GSEA analysis results, up-regulated autophagy genes and the impairing immune system are potential reasons resulting in DHF.

Conclusions

CD38, Plasma cells, activated memory CD4+ T cells and Monocytes can be used to distinguish clinical stages for dengue patients, and ZNF595 can be used to discriminate DHF from DF, regardless of serotypes.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
Zhang J, Shu Y, Shan X, Li D, Ma D, Li T, Long S, Wang X, Pan Y, Chen J, et al. Co-circulation of three dengue virus serotypes led to a severe dengue outbreak in Xishuangbanna, a border area of China, Myanmar, and Laos, in 2019. Int J Infect Dis. 2021;107:15–7.PubMedCrossRef
2.
Carbajo AE, Cardo MV, Vezzani D. Is temperature the main cause of dengue rise in non-endemic countries? the case of Argentina. Int J Health Geogr. 2012;11:26.PubMedPubMedCentralCrossRef
3.
Hiatt T, Nishikiori N. Epidemiology and control of tuberculosis in the Western Pacific Region: analysis of 2012 case notification data. Western Pac Surveill Response J. 2014;5:25–34.PubMedPubMedCentralCrossRef
4.
Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6: e1760.PubMedPubMedCentralCrossRef
5.
Inizan C, Minier M, Prot M, O’Connor O, Forfait C, Laumond S, Marois I, Biron A, Gourinat AC, Goujart MA, et al. Viral evolution sustains a dengue outbreak of enhanced severity. Emerg Microbes Infect. 2021;10:536–44.PubMedPubMedCentralCrossRef
6.
Thadchanamoorthy V, Dayasiri K. Postdengue chronic fatigue syndrome in an adolescent boy. BMJ Case Rep. 2021;14:e238605.PubMedCrossRef
7.
Kanesa-Thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak J, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik J. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 2001;19:3179–88.PubMedCrossRef
8.
Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo J-F. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24:1238–41.PubMedCrossRef
9.
Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33:7100–11.PubMedCrossRef
10.
Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014;14:830–8.PubMedPubMedCentralCrossRef
11.
Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg. 2015;93:454.PubMedPubMedCentralCrossRef
12.
Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol. 2008;82:6927–34.PubMedPubMedCentralCrossRef
13.
Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol. 2020;10: 572681.PubMedPubMedCentralCrossRef
14.
Narayan R, Tripathi S. Intrinsic ADE: the dark side of antibody dependent enhancement during dengue infection. Front Cell Infect Microbiol. 2020;10: 580096.PubMedPubMedCentralCrossRef
15.
16.
Malavige GN, Jeewandara C, Ghouse A, Somathilake G, Tissera H. Changing epidemiology of dengue in Sri Lanka-Challenges for the future. PLoS Negl Trop Dis. 2021;15: e0009624.PubMedPubMedCentralCrossRef
17.
18.
Eder M, Cortes F, Teixeira de Siqueira Filha N, Araújo de França GV, Degroote S, Braga C, Ridde V, Turchi Martelli CM. Scoping review on vector-borne diseases in urban areas: transmission dynamics, vectorial capacity and co-infection. Infect Dis Poverty. 2018;7:90.PubMedPubMedCentralCrossRef
19.
Mizushima N. A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol. 2018;20:521–7.PubMedCrossRef
20.
21.
Chu LW, Yang CJ, Peng KJ, Chen PL, Wang SJ, Ping YH. TIM-1 as a signal receptor triggers dengue virus-induced autophagy. Int J Mol Sci. 2019;20:4893.PubMedCentralCrossRef
22.
Lu ZY, Cheng MH, Yu CY, Lin YS, Yeh TM, Chen CL, Chen CC, Wan SW, Chang CP. Dengue nonstructural protein 1 maintains autophagy through retarding caspase-mediated cleavage of beclin-1. Int J Mol Sci. 2020;21:9702.PubMedCentralCrossRef
23.
Sun P, Nie K, Zhu Y, Liu Y, Wu P, Liu Z, Du S, Fan H, Chen CH, Zhang R, et al. A mosquito salivary protein promotes flavivirus transmission by activation of autophagy. Nat Commun. 2020;11:260.PubMedPubMedCentralCrossRef
24.
25.
Huang X, Yue Y, Li D, Zhao Y, Qiu L, Chen J, Pan Y, Xi J, Wang X, Sun Q, Li Q. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy. Sci Rep. 2016;6:22303.PubMedPubMedCentralCrossRef
26.
Yeo AS, Azhar NA, Yeow W, Talbot CC Jr, Khan MA, Shankar EM, Rathakrishnan A, Azizan A, Wang SM, Lee SK. Lack of clinical manifestations in asymptomatic dengue infection is attributed to broad down-regulation and selective up-regulation of host defence response genes. PLoS ONE. 2014;9: e92240.PubMedPubMedCentralCrossRef
27.
Simon-Lorière E, Duong V, Tawfik A, Ung S, Ly S, Casadémont I, Prot M, Courtejoie N, Bleakley K, Buchy P, et al. Increased adaptive immune responses and proper feedback regulation protect against clinical dengue. Sci Transl Med. 2017;9:eaal5088. PubMedCrossRef
28.
OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, Saborío S, Nuñez A, Lennon NJ, Birren BW, Gordon A, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med. 2011;3:114ra128.PubMedPubMedCentralCrossRef
29.
Garcia-Bates TM, Cordeiro MT, Nascimento EJ, Smith AP, de Melo KMS, McBurney SP, Evans JD, Marques ET, Barratt-Boyes SM. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol. 2013;190:80–7.PubMedCrossRef
30.
Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci. 2010;107:16922–7.PubMedPubMedCentralCrossRef
31.
Mlera L, Offerdahl DK, Dorward DW, Carmody A, Chiramel AI, Best SM, Bloom ME. The liver X receptor agonist LXR 623 restricts flavivirus replication. Emerg Microbes Infect. 2021;10:1378–89.PubMedPubMedCentralCrossRef
32.
Hong M, Tao S, Zhang L, Diao L-T, Huang X, Huang S, Xie S-J, Xiao Z-D, Zhang H. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13:166.PubMedPubMedCentralCrossRef
33.
Hill SR, Taparia T, Ignell R. Regulation of the antennal transcriptome of the dengue vector, Aedes aegypti, during the first gonotrophic cycle. BMC Genomics. 2021;22:71.PubMedPubMedCentralCrossRef
34.
Azlan A, Obeidat SM, Theva Das K, Yunus MA, Azzam G. Genome-wide identification of Aedes albopictus long noncoding RNAs and their association with dengue and Zika virus infection. PLoS Negl Trop Dis. 2021;15: e0008351.PubMedPubMedCentralCrossRef
35.
Jiang L, Ma D, Ye C, Li L, Li X, Yang J, Zhao Y, Xi J, Wang X, Chen J, et al. Molecular characterization of dengue virus serotype 2 cosmospolitan genotype from 2015 dengue outbreak in Yunnan, China. Front Cell Infect Microbiol. 2018;8:219.PubMedPubMedCentralCrossRef
36.
Wen S, Ma D, Lin Y, Li L, Hong S, Li X, Wang X, Xi J, Qiu L, Pan Y, et al. Complete genome characterization of the 2017 dengue outbreak in Xishuangbanna, a Border City of China, Burma and Laos. Front Cell Infect Microbiol. 2018;8:148.PubMedPubMedCentralCrossRef
37.
Wang X, Ma D, Huang X, Li L, Li D, Zhao Y, Qiu L, Pan Y, Chen J, Xi J, et al. Complete genome analysis of dengue virus type 3 isolated from the 2013 dengue outbreak in Yunnan, China. Virus Res. 2017;238:164–70.PubMedCrossRef
38.
Jiang L, Sun Q. The role of autophagy-mediated dengue virus antibody-dependent enhancement infection of THP-1 cells. Intervirology. 2020;63:57–65.PubMedCrossRef
39.
Zhong XL, Liao XM, Shen F, Yu HJ, Yan WS, Zhang YF, Ye JJ, Lv ZP. Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever. FEBS Open Bio. 2019;9:468–77.PubMedPubMedCentralCrossRef
40.
Xie LM, Yin X, Bi J, Luo HM, Cao XJ, Ma YW, Liu YL, Su JW, Lin GL, Guo XG. Identification of potential biomarkers in dengue via integrated bioinformatic analysis. PLoS Negl Trop Dis. 2021;15: e0009633.PubMedPubMedCentralCrossRef
41.
Sun P, García J, Comach G, Vahey MT, Wang Z, Forshey BM, Morrison AC, Sierra G, Bazan I, Rocha C, et al. Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity. PLoS Negl Trop Dis. 2013;7: e2298.PubMedPubMedCentralCrossRef
42.
Tolfvenstam T, Lindblom A, Schreiber MJ, Ling L, Chow A, Ooi EE, Hibberd ML. Characterization of early host responses in adults with dengue disease. BMC Infect Dis. 2011;11:209.PubMedPubMedCentralCrossRef
43.
Soares-Schanoski A, Baptista Cruz N, de Castro-Jorge LA, de Carvalho RVH, Santos CAD, Rós ND, Oliveira Ú, Costa DD, Santos C, Cunha MDP, et al. Systems analysis of subjects acutely infected with the Chikungunya virus. PLoS Pathog. 2019;15: e1007880.PubMedPubMedCentralCrossRef
44.
Kwissa M, Nakaya HI, Onlamoon N, Wrammert J, Villinger F, Perng GC, Yoksan S, Pattanapanyasat K, Chokephaibulkit K, Ahmed R, Pulendran B. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe. 2014;16:115–27.PubMedPubMedCentralCrossRef
45.
Wold S, Esbensen K, Geladi P. Principal component analysis. Chemom Intell Lab Syst. 1987;2:37–52.CrossRef
46.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545–50.PubMedPubMedCentralCrossRef
47.
Zhang B, Horvath S: A general framework for weighted gene co-expression network analysis. Statistical Applications in Genetics & Molecular Biology 2005, 4:Article17.
48.
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773–82.PubMedPubMedCentralCrossRef
49.
Nettleman MD. Receiver operator characteristic (ROC) curves. Infect Control Hosp Epidemiol. 1988;9:374–7.PubMedCrossRef
50.
51.
Chen T, Zhang H, Liu Y, Liu YX, Huang L. EVenn: Easy to create repeatable and editable Venn diagrams and Venn networks online. J Genet Genomics. 2021;48:863–6.PubMedCrossRef
52.
Castañeda DM, Salgado DM, Narváez CF. B cells naturally induced during dengue virus infection release soluble CD27, the plasma level of which is associated with severe forms of pediatric dengue. Virology. 2016;497:136–45.PubMedCrossRef
53.
Nguyen HD, Chaudhury S, Waickman AT, Friberg H, Currier JR, Wallqvist A. Stochastic model of the adaptive immune response predicts disease severity and captures enhanced cross-reactivity in natural dengue infections. Front Immunol. 2021;12: 696755.PubMedPubMedCentralCrossRef
54.
Zheng W, Wu H, Liu C, Yan Q, Wang T, Wu P, Liu X, Jiang Y, Zhan S. Identification of COVID-19 and dengue host factor interaction networks based on integrative bioinformatics analyses. Front Immunol. 2021;12: 707287.PubMedPubMedCentralCrossRef
55.
Zhou A, Dong X, Liu M, Tang B. Comprehensive transcriptomic analysis identifies novel antiviral factors against influenza A virus infection. Front Immunol. 2021;12: 632798.PubMedPubMedCentralCrossRef
56.
Wei J, Wang B, Gao X, Sun D. Prognostic value of a novel signature with nine hepatitis C virus-induced genes in hepatic cancer by mining GEO and TCGA databases. Front Cell Dev Biol. 2021;9: 648279.PubMedPubMedCentralCrossRef
57.
Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Déchelotte P, Bonnet M, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 2014;63:1932–42.PubMedCrossRef
58.
Deng M, Yin Y, Zhang Q, Zhou X, Hou G. Identification of inflammation-related biomarker Lp-PLA2 for patients with COPD by comprehensive analysis. Front Immunol. 2021;12: 670971.PubMedPubMedCentralCrossRef
59.
Tang BM, Shojaei M, Parnell GP, Huang S, Nalos M, Teoh S, O’Connor K, Schibeci S, Phu AL, Kumar A, et al. A novel immune biomarker IFI27 discriminates between influenza and bacteria in patients with suspected respiratory infection. Eur Respir J. 2017;49:1602098.PubMedCrossRef
60.
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762–9.PubMedCrossRef
Metadata
Title
Identification of stage-related and severity-related biomarkers and exploration of immune landscape for Dengue by comprehensive analyses
Authors
Nan Xiong
Qiangming Sun
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2022
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-022-01853-8

Other articles of this Issue 1/2022

Virology Journal 1/2022 Go to the issue

Research

Comprehensive virome analysis of the viral spectrum in paediatric patients diagnosed with Mycoplasma pneumoniae pneumonia

Research

Mechanism of autophagy induced by activation of the AMPK/ERK/mTOR signaling pathway after TRIM22-mediated DENV-2 infection of HUVECs

Correction

Correction to: In vitro anti-influenza assessment of anionic compounds ascorbate, acetate and citrate

Research

Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study

Review

Effect of herbal compounds on coronavirus; a systematic review and meta-analysis

Research

Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits